Sintilimab for the treatment of non-small cell lung cancer

• Autores principales: Lin Zhang (Autor), Weihao Lin (Autor), Fengwei Tan (Autor), Ning Li (Autor), Qi Xue (Autor), Shugeng Gao (Autor), Yibo Gao (Autor), Jie He (Autor)
• Formato: Libro
• Publicado: BMC, 2022-04-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunotherapy has dramatically changed the therapeutic landscape of inoperable non-small cell lung cancer (NSCLC), and has been included in first-line treatments. Sintilimab is a domestic anti-PD-1 monoclonal antibody in China...